Aggregated price index with volume information
Summary:
- Pharmaceuticals: Other stocks up 1.1% on average while median return up 0.8% in a day
- Pharmaceuticals: Other stocks down 1.6% on average while median return down 0.0% in a week
- Pharmaceuticals: Other stocks down 9.2% on average while median return down 6.4% in a month
- When average return is significantly different from median return, this implies an asymmetry - composite return is driven by some outliners.
Aggregated price index (close) is based on equal weighted constituencies returns. Average short volume and average total volumes are averaged across all volume data among constituencies.
- 1M winners are : Winners for past month are $RVMD 17.5%, $SCYX 11.5%, $ACRS 6.1%, $NAII 5.8%, $SAVA 3.7%
- 1M losers are : Losers for past month are $RVNC -24.8%, $OGI -28.3%, $SAGE -32.6%, $OCUL -47.3%, $MRNS -83.7%
- 1W winners are : Winners for past week are $MRNS 20.0%, $SCYX 9.9%, $AXSM 6.2%, $SLN 5.9%, $IRWD 5.3%
- 1W losers are : Losers for past week are $RGLS -11.7%, $ACST -14.6%, $HROW -16.1%, $SAGE -17.1%, $OCUL -35.8%
Correlation Analysis
Index correlation analysis
Correlation for the past month is 7.3%, for the past 3 months is 7.5%
In the past month for a 5 days rolling window, the highest corrrelation is 16.4%, the lowest correlation is -0.5%, the latest correlation is 5.5%
When a correlation deviated from the normal level and goes lower or even negative, it indicates some of stocks have deviated from the normal direction of the group. The deviation could reverse if long term level of correlation was at a higher level. It creates trading opportunities and deserves study whether the deviation is idiosyncratic or systematic.
Among pairwise correlation, the highest correlation is 66.4% between AXSM and IRWD
The lowest correlation is -67.7% between HZNP and ICPT
Corcept (CORT) reports positive data from the open-label portion of the phase III GRACE study evaluating relacorilant for treating patients with Cushing's syndrome.
Medical Products companies' quarterly results are likely to reflect a year-over-year decline in earnings. Let's see how BSX, TMO, ALGN and ICLR fare this time.
DENVER, April 23, 2024 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, and predominantly dual-eligible seniors through the Program of All-inclusive Care for the Elderly (PACE), today announced it will release its 2024 fiscal third quarter financial results on Tuesday, May 7, 2024, after market close. In conjunction, the Company will host a conference call to review the results at
CONSHOHOCKEN, Pa., April 23, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its first-quarter 2024 financial results on Tuesday, May 7, 2024, prior to the open of the U.S. financial markets. Following the announcement, Madrigal’s management will host a live webcast at 8 a.m. Eastern Time to review the Company’s financial and operating results. The live webcast may be accessed at the Investor Relations section of the Madrigal Pharmaceut
It is hard to get excited after looking at Innoviva's (NASDAQ:INVA) recent performance, when its stock has declined 10...
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
The Company will Host a Conference Call and Webcast on Thursday, May 9, 2024, at 8:30 AM ETCORAL GABLES, Fla., April 22, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its first quarter 2024 financial results after the market close
MENLO PARK, Calif., April 22, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol, today announced positive results from the open-label portion of the pivotal Phase 3 GRACE trial of its proprietary selective cortisol modulator relacorilant in patients with all etio
CAMBRIDGE, Mass. & SALISBURY, England, April 22, 2024--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that William C. Fairey has been appointed to the Company’s Board of Directors, effective immediately. Mr. Fairey was most recently the Chief Commercial Officer at MyoKardia, Inc., a clinical stage biopharmaceutical company, and is a bus
In the latest trading session, Siga Technologies Inc. (SIGA) closed at $8.34, marking a +1.34% move from the previous day.